Cellectis S.A.
CLLS
$1.53
$0.021.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5,397.35% | 76.24% | -21.12% | -70.85% | -96.06% |
| Total Other Revenue | -8.61% | -13.20% | -19.85% | -10.83% | 28.78% |
| Total Revenue | 435.32% | 46.95% | -20.70% | -52.39% | -64.26% |
| Cost of Revenue | -- | 6.66% | -30.34% | -46.86% | -58.41% |
| Gross Profit | 481.97% | 48.12% | -20.27% | -52.71% | -64.69% |
| SG&A Expenses | 13.52% | 36.03% | 8.83% | 3.40% | -3.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -383.95% | 83.05% | 99.51% | 112.29% | 121.71% |
| Total Operating Expenses | 3.11% | 16.89% | 2.92% | -2.26% | -8.58% |
| Operating Income | 38.16% | -6.80% | -10.26% | -13.07% | -7.40% |
| Income Before Tax | 68.44% | 15.35% | 27.01% | 15.15% | -18.12% |
| Income Tax Expenses | -100.00% | -212.64% | -199.42% | 24.14% | 325.29% |
| Earnings from Continuing Operations | 68.54% | 16.24% | 27.56% | 15.12% | -18.39% |
| Earnings from Discontinued Operations | -- | -100.00% | 100.00% | 196.23% | 154.69% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -34.20% | -6.46% |
| Net Income | 63.62% | 1.86% | 18.71% | 37.35% | 4.79% |
| EBIT | 38.16% | -6.80% | -10.26% | -13.07% | -7.40% |
| EBITDA | 44.05% | -7.85% | -12.28% | -19.14% | -11.93% |
| EPS Basic | 78.65% | 36.73% | 42.33% | 50.96% | 25.01% |
| Normalized Basic EPS | 79.89% | 47.95% | 36.42% | 30.99% | 4.38% |
| EPS Diluted | 65.45% | 23.39% | 31.20% | 40.85% | 25.25% |
| Normalized Diluted EPS | 78.58% | 46.63% | 35.11% | 29.69% | 4.38% |
| Average Basic Shares Outstanding | 58.81% | 57.00% | 42.50% | 32.20% | 25.34% |
| Average Diluted Shares Outstanding | 72.54% | 72.02% | 58.28% | 48.86% | 25.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |